Alexion Pharmaceuticals

Invivyd Announces the Appointment of Timothy Lee as Chief Commercial Officer

Retrieved on: 
星期五, 五月 31, 2024
COVID-19, Risk, Alexion Pharmaceuticals, Immunodeficiency, Timothy, History, Principal, Pharmaceutical industry

Mr. Lee joins Invivyd with a history of high-quality commercial execution at Alexion, Biohaven and Amylyx

Key Points: 
  • Mr. Lee joins Invivyd with a history of high-quality commercial execution at Alexion, Biohaven and Amylyx
    WALTHAM, Mass., May 31, 2024 (GLOBE NEWSWIRE) --  Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that Timothy Lee will be appointed Invivyd’s Chief Commercial Officer and will join the company’s executive leadership team.
  • In the ongoing transitional period, Invivyd’s Chief Financial Officer, William Duke, Jr. will assume the role of Principal Executive Officer, and the Board of Directors will continue its ongoing search for a permanent Chief Executive Officer.
  • I am confident that Tim is the right commercial leader to advance Invivyd’s evolution,” said Marc Elia, Chairman of the Invivyd Board of Directors.
  • Tim also previously held key commercial leadership roles across a variety of life science companies including Biohaven Pharmaceuticals and Alexion Pharmaceuticals.

Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer

Retrieved on: 
星期一, 五月 6, 2024
University, CFO, FASN, Inflammation, École des ponts ParisTech, Compensated emancipation, Alexion Pharmaceuticals, Employment, Intercept Pharmaceuticals, Novartis, Engineering, Patient, Black–Scholes model, Acquisition, MBA, Sanofi, SAN, Strategic planning, Management

SAN MATEO, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointment of Thierry Chauche as Chief Financial Officer, effective today, May 6, 2024.

Key Points: 
  • SAN MATEO, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointment of Thierry Chauche as Chief Financial Officer, effective today, May 6, 2024.
  • “We are thrilled to welcome Thierry to our executive leadership team in the role of CFO.
  • Thierry brings a proven track record in corporate finance in the biopharmaceutical sector, bringing expertise in corporate planning and strategy, investor relations, financing, and M&A,” said Dave Happel, CEO of Sagimet.
  • Before Provention Bio, Mr. Chauche was the Vice President and Head of Strategic Financial Planning & Analysis at Alexion Pharmaceuticals.

Rocket Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Progress

Retrieved on: 
星期一, 五月 6, 2024
Research, Genetics, Clinical Trials, Cardiology, Biotechnology, Health, Pharmaceutical, Science, Oncology, Education, FDA, CFO, Disorder, Regenerative medicine, University of California, Alexion Pharmaceuticals, PDUFA, Arena Pharmaceuticals, Danon disease, European Medicines Agency, Strategic planning, UCLA, Food, Molecule, Stanford University, Empire, BLA, Medication, Corporate communication, Definitive, Fanconi anemia, Patient, Increment, Safety, Rare disease, Regeneron Pharmaceuticals, AAV, Immunology, EMA, FA, Division, PKD, University, Marketing, MAA, Cell, Biologics license application, Pharmacology, Rare Disease Day, Disease, Mirati Therapeutics, Haematopoietic system, Gene, Society, Pyruvate kinase deficiency, Liberty Science Center, Annual general meeting, Pharmaceutical industry

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today reported financial and recent operational results for the quarter ending March 31, 2024.

Key Points: 
  • Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today reported financial and recent operational results for the quarter ending March 31, 2024.
  • In April, Rocket announced that the European Medicines Agency (EMA) accepted the Marketing Authorization Application (MAA) for RP-L102 for the treatment of FA.
  • MAA acceptance was based on positive, previously disclosed data from the global RP-L102 Phase 1/2 clinical trial.
  • Mr. Ondrey was previously the CFO at Mirati Therapeutics and has held multiple senior finance leadership positions at Arena Pharmaceuticals, Alexion Pharmaceuticals, and Regeneron Pharmaceuticals.

BrightSpring Health Services Specialty Pharmacy Onco360® Selected as National Pharmacy Partner for Voydeya®

Retrieved on: 
星期三, 四月 10, 2024
FDA, Cancer, Pharmacy, Hub, Blood, Eculizumab, Ravulizumab, Insurance, Alexion Pharmaceuticals, Disease, EVH, Patient, Haematopoietic system, Hemolysis, Alexion, Health care, Immune system, PNH, Quality of life, Anemia, Pharmaceutical industry

LOUISVILLE, Ky., April 10, 2024 (GLOBE NEWSWIRE) -- BrightSpring Health Services (“BrightSpring” or “BrightSpring Health Services”) (NASDAQ: BTSG) announced today that its company Onco360®, a leading independent oncology pharmacy, was selected as a national pharmacy partner by Alexion Pharmaceuticals for a first-in-class, oral, Factor D inhibitor, Voydeya® (Danicopan) to treat patients with a rare, life-threatening disease of the blood called paroxysmal nocturnal hemoglobinuria (PNH) who are experiencing extravascular hemolysis (EVH).

Key Points: 
  • LOUISVILLE, Ky., April 10, 2024 (GLOBE NEWSWIRE) -- BrightSpring Health Services (“BrightSpring” or “BrightSpring Health Services”) (NASDAQ: BTSG) announced today that its company Onco360®, a leading independent oncology pharmacy, was selected as a national pharmacy partner by Alexion Pharmaceuticals for a first-in-class, oral, Factor D inhibitor, Voydeya® (Danicopan) to treat patients with a rare, life-threatening disease of the blood called paroxysmal nocturnal hemoglobinuria (PNH) who are experiencing extravascular hemolysis (EVH).
  • Voydeya® is FDA-approved as add-on therapy to Ultomiris® (Ravulizumab) or Soliris® (Eculizumab) for patients living with PNH that experience continued anemia, or EVH.
  • This innovative drug will complement current treatment regimens and help regulate the immune system, providing control and preventing the destruction of healthy blood cells.
  • To learn more about Onco360® and BrightSpring, please visit https://www.brightspringhealth.com/ .

PharmaEssentia Appoints Robert Geller, M.D. as Head of Medical and Shawn Gibbs, J.D. as Head of Legal

Retrieved on: 
星期三, 四月 24, 2024
Research, Legal, Clinical Trials, Professional Services, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Shawn, Massachusetts Institute of Technology, University, Vion Pharmaceuticals, Optimer Pharmaceuticals, Physics, Pancreatic serous cystadenoma, Safety, Pharmacovigilance, Hematology, GE HealthCare, Grinnell College, Partnership, Alexion Pharmaceuticals, Partner, Senior, Corporate lawyer, Patient, Medicine, Multimedia, Marketing, Drug development, Harvard Medical School, Associate, Trade, Ophthalmology, Ovarian cancer, Gerber Products Company, Platinum, Strategic planning, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20240423922725/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240423922725/en/
    Dr. Robert Geller is a medical oncologist with diverse expertise across the biotechnology industry and in academia, including in drug development, medical affairs, business development and as a clinical scientist.
  • As the new Head of Medical at PharmaEssentia, Dr. Geller will be responsible for U.S. clinical operations, reporting to Chief Medical Officer, Albert Qin, M.D., Ph.D.
  • joins PharmaEssentia with extensive experience across legal affairs in the biopharmaceutical industry, including in corporate transactions, governance, compliance, litigation, regulatory matters, and strategic planning.
  • Prior, he held several legal positions with Sequirus, Inc., including most recently Executive Director, Associate General Counsel, Americas, within Commercial Development and Medical Affairs.

Obsidian Therapeutics Appoints Jeffrey Trigilio as Chief Financial Officer

Retrieved on: 
星期一, 四月 15, 2024
Biotechnology, Health, Genetics, Pharmaceutical, Oncology, Credit Suisse, Corporate finance, RBC Capital Markets, Amylyx Pharmaceuticals, Alexion Pharmaceuticals, Cornell University, TIL, Record, Columbia Business School, Therapy, Growth

Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced the appointment of Jeffrey Trigilio as Chief Financial Officer, effective May 1, 2024.

Key Points: 
  • Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced the appointment of Jeffrey Trigilio as Chief Financial Officer, effective May 1, 2024.
  • “We are thrilled to welcome Jeff to the Obsidian leadership team as the company’s Chief Financial Officer,” said Madan Jagasia, M.D., Chief Executive Officer of Obsidian.
  • Most recently, he served as Chief Financial Officer of Cullinan Oncology, where he guided its initial public offering and helped secure several business development transactions for its portfolio.
  • Before Cullinan, Mr. Trigilio served as Chief Financial Officer for Amylyx Pharmaceuticals, Vice President of Corporate Finance at BlueRock Therapeutics, and in various corporate strategy and finance roles at Alexion Pharmaceuticals.

Onco360 Has Been Selected as the Sole National Specialty Pharmacy Partner for Voydeya® (danicopan)

Retrieved on: 
星期一, 四月 8, 2024
Immune system, PNH, Specialty pharmacy, Patient, Ravulizumab, FDA, Eculizumab, Paroxysmal nocturnal hemoglobinuria, EVH, Blood, Alexion Pharmaceuticals

LOUISVILLE, Ky., April 08, 2024 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a national pharmacy partner by Alexion Pharmaceuticals for Voydeya® (Danicopan) as a first class oral, Factor D inhibitor.

Key Points: 
  • LOUISVILLE, Ky., April 08, 2024 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a national pharmacy partner by Alexion Pharmaceuticals for Voydeya® (Danicopan) as a first class oral, Factor D inhibitor.
  • It is FDA-approved for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH) in combination with C5 inhibitor, Ultomiris® (Ravulizumab) or Soliris® (Eculizumab) for patients that experience clinically significant extravascular hemolysis (EVH).1 Voydeya® is an oral, Factor D inhibitor that acts in the alternative complement pathway of the immune system, providing control of red blood cell destruction within and outside the blood vessels.
  • “Onco360 appreciates the opportunity to partner further with the team at Alexion and become the sole national specialty pharmacy provider for Voydeya®”, said Benito Fernandez, Chief Commercial Officer.
  • “We are proud to add this first in class oral Factor D inhibitor treatment option for PNH patients.”

Rocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership Team

Retrieved on: 
星期二, 三月 26, 2024
Biotechnology, Pharmaceutical, Genetics, Health, Research, Financial management, Mirati Therapeutics, Medication, Regeneron Pharmaceuticals, Alexion Pharmaceuticals, CFO, General counsel, Patient, Pharming, Strategic planning, Arena Pharmaceuticals, Acquisition, Bristol Myers Squibb, Drug, MBA, Marketing, Drug development, Access, Disorder, Corporate development

Aaron Ondrey joins Rocket as Chief Financial Officer, bringing more than 20 years of experience in financial management, strategic planning, commercial finance, capital allocation and mergers and acquisitions having held multiple finance leadership positions across the pharma and biotech industry.

Key Points: 
  • Aaron Ondrey joins Rocket as Chief Financial Officer, bringing more than 20 years of experience in financial management, strategic planning, commercial finance, capital allocation and mergers and acquisitions having held multiple finance leadership positions across the pharma and biotech industry.
  • Prior to Mirati, Mr. Ondrey also held senior leadership positions at Arena Pharmaceuticals, Alexion Pharmaceuticals, and Regeneron Pharmaceuticals.
  • The key appointments within Rocket’s existing corporate leadership team are as follows:
    Kinnari Patel, Pharm.D., MBA, has been appointed President, Head of R&D and Chief Operating Officer.
  • J.D., has been appointed General Counsel & Chief Corporate Officer, and will lead Legal, Compliance, and Corporate Development.

Alexion Canada Appoints Karen Heim as New General Manager

Retrieved on: 
星期二, 四月 2, 2024
Circulatory system, Neurology, AstraZeneca, GSK plc, Metabolism, Hematology, Cardiology, Patient, DSM-IV codes, Research, Alexion Pharmaceuticals, Bachelor of Science, Acquisition, University, Senior, Metallurgy, Nephrology, Queen's University, Rare disease, Immunity (medical), Alexion, Ophthalmology, Pharmaceutical industry

MISSISSAUGA, ON, April 2, 2024 /CNW/ - Alexion Pharma Canada Corp., AstraZeneca's Rare Disease group, is pleased to announce the appointment of Karen Heim as Vice President and General Manager, Canada, effective April 1st, 2024.

Key Points: 
  • MISSISSAUGA, ON, April 2, 2024 /CNW/ - Alexion Pharma Canada Corp., AstraZeneca's Rare Disease group, is pleased to announce the appointment of Karen Heim as Vice President and General Manager, Canada, effective April 1st, 2024.
  • In this role, Ms. Heim will lead the Canadian affiliate in its unwavering commitment to helping people affected by rare diseases live longer, healthier lives.
  • "Karen's deep healthcare experience and incredible passion make her the perfect fit to lead this mission in Canada and drive it with expertise and ambition."
  • "Taking on this leadership role at Alexion Canada as it continues to grow, with a focus on research and innovation, is incredibly exciting," says Ms. Heim.

AEOVIAN PHARMACEUTICALS DOSES FIRST PARTICIPANTS IN PHASE 1 CLINICAL TRIAL, STRENGTHENS LEADERSHIP TEAM AND RAISES ADDITIONAL $50 MILLION FINANCING

Retrieved on: 
星期四, 三月 28, 2024
Xenon, TSC, Epilepsy, Alexion Pharmaceuticals, Patient, Sale, Investment, Therapy, Melinda French Gates, Jazz Pharmaceuticals, Genetic disorder, Ageing, CIO, Notifiable disease, Biotechnology, Yale University, CNS, NIH, Zajac, University of Bristol, Honours degree, UCSF, Drug discovery, Evotec, GW Pharmaceuticals, Genetic distance, DSM-IV codes, Wesleyan University, Growth, CFO, BIO, Record, Bachelor of Science, Morgan Stanley, Former, Pharmaceutical industry

BERKELEY, Calif., March 28, 2024 /PRNewswire/ -- Aeovian Pharmaceuticals, a clinical-stage biopharmaceutical company developing novel and highly selective therapeutics that potently inhibit the mTORC1 pathway, today announced that it has dosed the first cohort of participants in a Phase 1 clinical trial for its lead development candidate AV078, a first-in-class CNS penetrant selective mTORC1 inhibitor. Supporting this transition into the clinic, the company has also expanded its leadership team with the appointment of seasoned industry veterans William Greene, M.D., Chief Investment Officer at Hevolution, and Justin Gover, former Chief Executive Officer of GW Pharmaceuticals, to the company's Board of Directors, and appointed Micah Zajic as Chief Financial Officer. The company also recently completed a $50 million financing, led by Hevolution.

Key Points: 
  • Aeovian has assembled a compelling platform for the development of selective mTORC1 inhibitors," said Dr. Greene, CIO at Hevolution.
  • In the $50M financing, Hevolution was joined by existing investors Apollo Health Ventures, Sofinnova Investments, venBio, Evotec and b2venture.
  • This financing will support the completion of the Phase 1 clinical trial in healthy volunteers and prepare for the start of a subsequent Phase 2 clinical trial in adult and pediatric patients with TSC refractory epilepsy.
  • As CEO, he built and led Iconic Therapeutics through discovery, clinical development, and venture financing, which culminated in a successful sale of the company.